Aquaporin-4 antibody titration in NMO patients treated with rituximab
A retrospective study
Citation Manager Formats
Make Comment
See Comments

Abstract
Objective: We undertook an observational retrospective study to investigate the usefulness of aquaporin-4 (AQP4) antibodies (Ab) titration in the management of patients with neuromyelitis optica (NMO) treated with rituximab (RTX) by studying (1) the correlation between AQP4-Ab titer and disease activity, (2) the influence of RTX on antibody levels, and (3) the association between AQP4-Ab levels and responsiveness to RTX.
Methods: A cell-based assay was used for AQP4-Ab titration in 322 serum samples from 7 patients with NMO treated with RTX (median follow-up 65 months), according to a treatment-to-target approach. Serum samples were collected every month following standardized procedures.
Results: (1) In group analysis, AQP4-Ab titers correlated with the disease activity, showing higher titers during and preceding relapses than during remission. However, in individual analysis, an increase in AQP4-Ab titers and CD19+ B cells did not always precede a relapse. (2) A reduction of AQP4-Ab titers in the short-term and long-term period was observed during RTX treatment. (3) Reduction of AQP4-Ab titers was observed in responder patients both 3 months after RTX infusion and in the long-term follow-up. In one nonresponder patient, AQP4-Ab levels never decreased during the treatment period.
Conclusions: Titration of AQP4-Abs could be useful in the clinical management of patients with NMO treated with RTX: titration before each reinfusion and 3 months after each reinfusion may provide information about responsiveness to RTX. Although a relationship among AQP4-Ab levels, disease activity, and response to RTX was observed, the usefulness of AQP4-Ab titration to predict relapses is limited.
GLOSSARY
- Abs=
- antibodies;
- AQP4=
- aquaporin-4;
- ARR=
- annual relapse rate;
- CBA=
- cell-based assay;
- CRESM=
- Regional Referring Centre for Multiple Sclerosis;
- EDSS=
- Expanded Disability Status Scale;
- FC=
- flow cytometric;
- IFI=
- indirect immunofluorescence;
- NMO=
- neuromyelitis optica;
- RTX=
- rituximab
Footnotes
Funding information and disclosures are provided at the end of the article. Go to Neurology.org/nn for full disclosure forms. The Article Processing Charge was paid by Fondazione per la Ricerca Biomedica.
Supplemental data at Neurology.org/nn
- Received June 29, 2016.
- Accepted in final form November 1, 2016.
- Copyright © 2016 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology
This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License 4.0 (CC BY-NC-ND), which permits downloading and sharing the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.
Letters: Rapid online correspondence
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Hastening the Diagnosis of Amyotrophic Lateral Sclerosis
Dr. Brian Callaghan and Dr. Kellen Quigg
► Watch
Topics Discussed
Alert Me
Recommended articles
-
Article
Rituximab monitoring and redosing in pediatric neuromyelitis optica spectrum disorderMargherita Nosadini, Gulay Alper, Catherine J. Riney et al.Neurology - Neuroimmunology Neuroinflammation, January 21, 2016 -
Article
Disability Outcomes in the N-MOmentum Trial of Inebilizumab in Neuromyelitis Optica Spectrum DisorderRomain Marignier, Jeffrey L. Bennett, Ho Jin Kim et al.Neurology: Neuroimmunology & Neuroinflammation, March 26, 2021 -
Article
Extending rituximab dosing intervals in patients with MS during the COVID-19 pandemic and beyond?Adil Maarouf, Audrey Rico, Clemence Boutiere et al.Neurology: Neuroimmunology & Neuroinflammation, June 25, 2020 -
Article
Responsiveness to reduced dosage of rituximab in Chinese patients with neuromyelitis opticaChun-Sheng Yang, Li Yang, Ting Li et al.Neurology, July 24, 2013